reviewTop 10% cited
Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications
European Radiology · 2004 · Vol. 14(4) · pp. 559–578
Peter Reimer✉(University of Freiburg)Guenther Schneider(Saarland University)Wolfgang Schima(University of Vienna)
Liver Disease Diagnosis and TreatmentHepatocellular Carcinoma Treatment and PrognosisLiver Disease and TransplantationMedicineNeuroradiologyContrast (vision)RadiologyInterventional radiologyMagnetic resonance imagingBolus (digestion)CirrhosisNuclear medicineSurgery
MeSH terms
Contrast MediaEdetic AcidGadoliniumHumansLiverLiver DiseasesLiver NeoplasmsMagnetic Resonance ImagingManganeseMeglumineOrganometallic CompoundsPyridoxal PhosphateTime FactorsTomography, X-Ray ComputedGadolinium DTPA
Citations
284
FWCI
7.70
field-weighted impact
References
83
Percentile
98%
vs. same field & year
Citations per year
Cited by
Comprehensive review of imaging modalities for diagnosis and characterization of focal liver lesions
International Journal of Radiology and Diagnostic Imaging · 2024 · 0 citations
References
Ferucarbotran (Resovist): a new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: properties, clinical development, and applications
European Radiology · 2003 · 612 citations
Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging
European Radiology · 2001 · 1,375 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.